Regadenoson Stress-MRI to Identify Coronary Artery Disease in Atrial Fibrillation Patients

Completed · Phase 2

Conditions studied: Atrial Fibrillation, Coronary Artery Disease

In brief

Atrial fibrillation (AF) is growing into an epidemic affecting 1 in 4 adults. There is a need for research to elucidate the prevalence of ischemic cardiomyopathy in patients diagnosed with AF. The objective of this study is to demonstrate the utility of MRI in assessment of coronary artery disease. The specific objective is to demonstrate sensitivity/specificity comparable to that reported in meta-analyses of non-AF patients and adenosine (90% /80%) in an AF population using the time-efficient vasodilator regadenoson that requires only a single intravenous (IV).

Key facts

Study ID

NCT01710254

Run by

University of Utah

People needed

30

Starts

2013-01-01

Expected to finish

2016-10-01

Last updated by the study team

2017-12-13

Who can join

Age: 18 and older, up to 100. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with confirmed persistent or paroxysmal AF and suspected coronary artery disease who will undergo catheterization X-ray angiography

You may not qualify if…

• Critically ill patients, patients on ventilators patients with hypotension, asthmatics, and other patients whose medical care or safety may be compromised from undergoing an MRI examination will be excluded.
• Patients with claustrophobia will also be excluded since MRI is conducted in a closed environment.
• Patients with contraindications to MRI (pacemaker, metal implants).
• Pregnant subjects (or women who may become pregnant), minors, and prisoners will be excluded from this study.
• Subjects are over 60 or have any suspicion of abnormal kidney function (a blood test to determine Glomerular filtration rate (GFR) will be performed prior to imaging. Subjects with GFR<30 will be excluded from the study. This is standard practice for clinical scans in Radiology due to the extremely small but not negligible relationship between gadolinium contrast agent and nephrogenic systemic fibrosis in patients with severely impaired renal function.

Where it is running

• University of Utah — Salt Lake City, Utah, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.